Global Cell & Gene Therapy Manufacturing Services Market Size study & Forecast, by Type (Allogeneic, Autologous, Viral Vector, Non-viral Vector), Indication (Oncology, Orthopedic, Ophthalmology), Application (Clinical, Commercial), End User (Pharma, Biote

The Global Cell & Gene Therapy Manufacturing Services Market, valued at approximately USD 7.04 billion in 2024, is projected to expand at a striking CAGR of 17.50% from 2025 to 2035. As the life sciences sector pushes the boundaries of modern medicine, cell and gene therapy manufacturing services have emerged as a vital bridge between groundbreaking research and large-scale therapeutic delivery. These specialized services encompass a broad spectrum of capabilities—from process development and viral vector production to commercial-scale manufacturing—enabling biopharmaceutical companies to accelerate the translation of advanced therapies into market-ready treatments. Increasing incidences of genetic disorders, a growing pipeline of cell and gene therapy candidates, and regulatory incentives for regenerative medicine are collectively propelling the market forward. Meanwhile, advancements in automation, closed-system manufacturing, and scalable bioprocessing platforms are redefining efficiency, cost-effectiveness, and global accessibility of these life-saving modalities.

The momentum within this market is further amplified by the exponential growth in oncology-focused therapies, with CAR-T and TCR-based treatments leading the charge. These transformative therapies demand highly controlled, GMP-compliant environments and expert handling, pushing pharmaceutical and biotech firms to seek specialized contract development and manufacturing organizations (CDMOs) with deep technical expertise. Moreover, the rise of allogeneic approaches promises to overcome the scalability and cost challenges associated with autologous therapies, broadening patient accessibility. As precision medicine gains wider adoption, demand for flexible manufacturing capacities capable of rapid scale-up for both clinical trials and commercial distribution is soaring. Industry collaborations, multi-site manufacturing footprints, and robust quality management systems are becoming non-negotiable for success in this rapidly evolving landscape.

Regionally, North America is anticipated to command the largest share of the market in 2025, bolstered by its strong biotechnology ecosystem, high concentration of clinical trials, and advanced regulatory frameworks that support expedited approval pathways for regenerative medicines. Europe continues to strengthen its position through substantial investments in manufacturing infrastructure, collaborative R&D networks, and supportive funding programs from the European Medicines Agency and national governments. Meanwhile, Asia Pacific is expected to witness the fastest growth over the forecast period, driven by increasing government investment in biotechnology hubs, the rise of contract manufacturing in countries like China, South Korea, and Singapore, and an expanding patient pool for genetic and oncology disorders. The region’s growing capabilities in cost-efficient manufacturing, coupled with favorable regulatory reforms, are attracting global players to establish production partnerships and innovation centers in the region.

Major market players included in this report are:
• Lonza Group AG
• Catalent, Inc.
• WuXi AppTec Co., Ltd.
• Thermo Fisher Scientific Inc.
• Samsung Biologics
• Fujifilm Diosynth Biotechnologies
• Bluebird Bio, Inc.
• Oxford Biomedica plc
• Boehringer Ingelheim International GmbH
• Novartis AG
• Takara Bio Inc.
• BioNTech SE
• Charles River Laboratories International, Inc.
• Cell and Gene Therapy Catapult
• Kite Pharma, Inc.

Global Cell & Gene Therapy Manufacturing Services Market Report Scope:
• Historical Data – 2023, 2024
• Base Year for Estimation – 2024
• Forecast period - 2025-2035
• Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study. The report also provides detailed information about crucial aspects, such as driving factors and challenges, which will define the future growth of the market. Additionally, it incorporates potential opportunities in micro-markets for stakeholders to invest, along with a detailed analysis of the competitive landscape and product offerings of key players.

The detailed segments and sub-segments of the market are explained below:

By Type:
• Allogeneic
• Autologous
• Viral Vector
• Non-viral Vector

By Indication:
• Oncology
• Orthopedic
• Ophthalmology

By Application:
• Clinical
• Commercial

By End User:
• Pharma
• Biotech

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC

Latin America
• Brazil
• Mexico

Middle East & Africa
• UAE
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2025 to 2035.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions. Show more